Hospital
Range Regional Health Services
Range Regional Health Services was paid $23.67M by Medicaid between Jan 2018 and Dec 2024, across 152 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 46% of everything it billed.
33Billing provider infoRANGE REGIONAL HEALTH SERVICES
HIBBING, MN 55746
HIBBING, MN 55746
33aNPI1356321699assigned 01/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.67M
24GClaims415,200
24DCodes billed152
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#13 of 36
Median peer was paid$11.46M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,611 | $1.50M | |
| 2019 | 64,043 | $4.09M | |
| 2020 | 47,886 | $2.95M | |
| 2021 | 61,320 | $3.70M | |
| 2022 | 61,913 | $4.03M | |
| 2023 | 65,430 | $4.02M | |
| 2024incomplete | 46,997 | $3.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 46% | 137,176 | 121,853 | $10.80M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 12,792 | 11,711 | $3.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 21,512 | 18,179 | $2.52M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.8% | 33,842 | 31,147 | $1.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.5% | 11,130 | 9,518 | $1.06M |
| 36415 | Collection of venous blood by venipuncture | 4.2% | 47,192 | 42,470 | $999K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 2.7% | 14,676 | 3,622 | $642K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 3,981 | 3,877 | $466K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 2,992 | 2,816 | $376K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.2% | 6,336 | 5,809 | $296K |
| 99223 | Prolong inpt eval add15 m | <1% | 2,046 | 1,918 | $222K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,238 | 2,162 | $157K |
140 more codes
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,485 | $157K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 2,313 | $154K |
| 80053 | Comprehensive metabolic panel | <1% | 17,069 | $153K |
| X5622 | <1% | 488 | $113K | |
| 90837 | Psychotherapy session, about an hour | <1% | 676 | $77K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,146 | $75K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,110 | $69K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,353 | $60K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,240 | $59K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,202 | $58K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,145 | $52K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 736 | $51K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,628 | $50K |
| 92557 | <1% | 670 | $48K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,079 | $48K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 10,389 | $43K |
| 11721 | <1% | 1,638 | $43K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 588 | $39K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,019 | $37K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,610 | $34K |
| 71045 | Radiologic examination, chest; single view | <1% | 549 | $33K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 570 | $32K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 618 | $29K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 374 | $22K |
| 80061 | Lipid panel | <1% | 1,873 | $22K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 91 | $21K |
| 92567 | <1% | 1,181 | $21K | |
| 11056 | <1% | 155 | $19K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 355 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,207 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,398 | $16K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 91 | $13K |
| 92504 | <1% | 1,085 | $12K | |
| 81001 | <1% | 5,611 | $11K | |
| 0002A | <1% | 528 | $10K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 190 | $9K |
| 80306 | <1% | 691 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 284 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 529 | $7K |
| 87631 | <1% | 270 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 284 | $7K |
| 36416 | <1% | 134 | $7K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 581 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 316 | $6K |
| 73630 | <1% | 125 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 70 | $6K |
| 84484 | <1% | 912 | $6K | |
| 92552 | <1% | 80 | $6K | |
| 99442 | <1% | 138 | $5K | |
| 86140 | <1% | 1,164 | $5K | |
| 83690 | <1% | 940 | $5K | |
| 99221 | <1% | 97 | $5K | |
| 83605 | <1% | 1,256 | $5K | |
| 92550 | <1% | 80 | $5K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 774 | $5K |
| 97597 | <1% | 47 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 24 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 51 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 699 | $4K |
| 0001A | <1% | 277 | $4K | |
| 90686 | <1% | 711 | $4K | |
| 87210 | <1% | 453 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 25 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,170 | $3K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 152 | $3K |
| 85610 | <1% | 448 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 29 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 41 | $3K |
| 31231 | <1% | 14 | $3K | |
| 86780 | <1% | 111 | $3K | |
| 92556 | <1% | 90 | $3K | |
| 77336 | <1% | 23 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,133 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,632 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 29 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 67 | $1K |
| 91320 | <1% | 29 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,249 | $1K |
| 82077 | <1% | 145 | $1K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 206 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 879 | $1K |
| 99441 | <1% | 47 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 48 | $1K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 43 | $1K |
| 90480 | <1% | 42 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 363 | $960.71 |
| 87081 | <1% | 893 | $943.71 | |
| 83735 | <1% | 150 | $856.13 | |
| 85027 | <1% | 820 | $851.80 | |
| 0054A | <1% | 29 | $841.28 | |
| 0124A | <1% | 26 | $812.25 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 18 | $691.29 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 39 | $542.01 |
| 0352U | <1% | 13 | $503.52 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 685 | $453.72 |
| J2704 | Injection, propofol, 10 mg | <1% | 785 | $435.81 |
| 86803 | <1% | 26 | $413.34 | |
| 0072A | <1% | 13 | $384.86 | |
| 0031A | <1% | 14 | $383.95 | |
| 0004A | <1% | 17 | $361.91 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 38 | $317.22 |
| 93016 | <1% | 28 | $310.23 | |
| 92551 | <1% | 27 | $309.75 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 417 | $303.92 |
| 83615 | <1% | 129 | $286.28 | |
| 83655 | <1% | 28 | $228.81 | |
| 74019 | <1% | 12 | $223.82 | |
| 86850 | <1% | 41 | $220.27 | |
| 93018 | <1% | 28 | $205.93 | |
| 82607 | <1% | 15 | $194.40 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 39 | $189.69 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 364 | $148.29 |
| 96127 | <1% | 14 | $139.88 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 46 | $135.97 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 208 | $126.00 |
| 90656 | <1% | 50 | $109.82 | |
| 88304 | <1% | 13 | $106.08 | |
| 82248 | <1% | 26 | $101.82 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 85 | $97.80 |
| 85379 | <1% | 17 | $79.10 | |
| 94726 | <1% | 13 | $76.92 | |
| 82570 | <1% | 40 | $67.22 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 30 | $65.81 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 16 | $65.01 |
| 81025 | <1% | 81 | $60.88 | |
| 94729 | <1% | 13 | $56.51 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $34.56 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 26 | $11.88 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13 | $0.24 |
| 90677 | <1% | 40 | $0.05 | |
| 90697 | <1% | 12 | $0.01 | |
| 90670 | <1% | 17 | $0.01 | |
| 99000 | 0% | 189 | $0.00 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 0% | 12 | $0.00 |
| 90633 | 0% | 25 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 53 | $0.00 |
| 81003 | 0% | 15 | $0.00 | |
| 98940 | 0% | 36 | $0.00 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 0% | 14 | $0.00 |
| 93017 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHRISTENSEN, TODD (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Grand Itasca Clinic and Hospital | Grand Rapids, MN | $25.15M |
| Sun Mountain Dental Care LLC | Wasilla, AK | $1.08M |
| Advanced Family Dental Care | Anchorage, AK | $609K |
| Fairbanks Family Dental Care INC | Fairbanks, AK | $220K |
| Sonora Anesthesia Services a Medical Group INC | Sonora, CA | $712.80 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.